Stockchase Opinions

Stephanie Link, Chief investment strategist, HightowerNateraNTRABUYAug 07, 2026

Is soaring on earnings: they beat and raise. Their signature disease test outperformed and boasts a total addressable market of $7 billion. They are tops in this space. Great managers.

$322.10

Stock price when the opinion was issued

$310.78

As of Aug 13, 2026. Market Open.

Healthcare
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

PARTIAL SELL

Trimmed it because it moved up 145% the past year. They have a great franchise in cancer detection recurrence. Likes it long-term.

BUY

A biotech that does, among other things, cancer testing which is very accurate.. She just bought it. Is growing fast and expects it to be cash-flow positive this year.

BUY
He believes in this space, diagnostics. NTRA can make an acquiring company a nice piece of change.